Kempharm Earnings Estimate

KMPH -  USA Stock  

USD 10.75  0.24  2.18%

Many public companies, such as Kempharm, manage the perception of their earnings on regular basis to make sure that analyst estimates are accurate. Future earnings calculations are essential input when attempting to value a firm.
Kempharm is projected to generate 0.625 in earnings per share on 31st of December 2021. Kempharm earnings estimates module stress-tests analyst consensus about projected Kempharm EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Please see Stocks Correlation.

Search Earnings Estimates 

 
Refresh
The current Gross Profit is estimated to increase to about 14.6 M, while Profit Margin is projected to decrease to (1.04) .

Kempharm Earnings Estimation Breakdown

Calculation of earning per share of Kempharm is based on official Zacks consensus of 1 analysts regarding Kempharm future annual earnings. Given the historical accuracy of 67.91%, the future earnings per share of Kempharm is estimated to be 0.625 with the lowest and highest values of 0.61 and 0.64, respectively. Please note that this consensus of annual earnings estimates for Kempharm is an estimate of EPS before non-recurring items and including employee stock options expenses
Current EPS
-6.83
29th of July 2021
0.61
Lowest
Estimated EPS
0.625
0.64
Highest

Kempharm Earnings Projection Consensus

Suppose the current estimates of Kempharm's value are higher than the current market price of the Kempharm stock. In this case, investors may conclude that Kempharm is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Kempharm's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyCurrent EPSEPS Estimate for 31st of December 2021

1

67.91%

-6.83

0.625

Kempharm Earnings History

Earnings estimate consensus by Kempharm analysts from Wall Street is used by the market to judge Kempharm's stock performance. The investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Kempharm's upcoming profit reports and earnings-per-share forecasts but also compare them to our different valuation methods.

Kempharm Quarterly Earnings Before Interest Taxes and Depreciation Amortization EBITDA

(10.03 Million)Share
The current Accumulated Retained Earnings Deficit is estimated to decrease to about (265.3 M). The current Earning Before Interest and Taxes EBIT is estimated to decrease to about (8.6 M) Kempharm Weighted Average Shares is most likely to increase significantly in the upcoming years. The last year's value of Weighted Average Shares was reported at 3.98 Million. The current Weighted Average Shares Diluted is estimated to increase to about 4.3 M, while Issuance Purchase of Equity Shares is projected to decrease to roughly 22.8 M.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Kempharm's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Kempharm in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
7.1010.6814.26
Details
Intrinsic
Valuation
LowReal ValueHigh
9.5213.1016.68
Details
2 Analysts
Consensus
LowTarget PriceHigh
10.0019.0028.00
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Kempharm. Your research has to be compared to or analyzed against Kempharm's peers to derive any actionable benefits. When done correctly, Kempharm's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Kempharm. Note that many institutional investors and large investment bankers can move markets due to the volume of Kempharm assets they manage. They also follow analysts to some degree and often drive overall investor sentiments towards Kempharm. With so many stockholders watching consensus numbers, the difference between actual and projected earnings is one of the most critical factors driving Kempharm stock price in the short term.

Kempharm Earnings per Share Projection vs Actual

Actual Earning per Share of Kempharm refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Kempharm predict the company's earnings will be in the future. The higher the earnings per share of Kempharm, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Kempharm Estimated Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Kempharm, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Kempharm should always be considered in relation to other companies to make a more educated investment decision.

Kempharm Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Kempharm's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-05-13
2021-03-31-0.17-2.49-2.321364 
2021-03-11
2020-12-31-0.67-1.07-0.459 
2020-10-29
2020-09-30-0.8-0.640.1620 
2020-08-12
2020-06-3000.160.16
2020-05-12
2020-03-310.16-1.92-2.081300 
2020-02-28
2019-12-31-2.24-1.60.6428 
2019-11-14
2019-09-30-4.480.965.44121 
2019-08-13
2019-06-30-6.88-5.281.623 
2019-05-14
2019-03-31-6.72-7.36-0.64
2019-02-28
2018-12-31-8.8-3.25.663 
2018-11-08
2018-09-30-13.4933-15.04-1.546711 
2018-08-09
2018-06-30-15.64-10.45.2433 
2018-05-10
2018-03-31-10.8-28.32-17.52162 
2018-03-29
2017-12-31-10.88-11.52-0.64
2017-11-09
2017-09-30-10.7733-10.88-0.1067
2017-08-10
2017-06-30-10.1867-7.043.146730 
2017-05-10
2017-03-31-10.08-13.44-3.3633 
2017-03-09
2016-12-31-9.6-10.88-1.2813 
2016-11-09
2016-09-30-9.28-14.72-5.4458 
2016-08-10
2016-06-30-11.36-9.282.0818 
2016-05-12
2016-03-31-7.3067-3.24.106756 
2016-03-10
2015-12-31-0.53-0.64-0.1120 
2015-11-12
2015-09-30-0.42-0.68-0.2661 
2015-08-13
2015-06-30-0.42-2.45-2.03483 
2015-04-15
2015-03-31-0.47-2.5-2.03431 

About Kempharm Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Kempharm earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Kempharm estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Kempharm fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for 2021
Accumulated Retained Earnings Deficit-258.5 M-265.3 M
Earning Before Interest and Taxes EBIT-8 M-8.6 M
Earnings per Basic Share(3.21) (3.46) 
Earnings per Diluted Share(3.21) (3.46) 
Price to Earnings Ratio(3.49) (3.76) 
Earnings Before Interest Taxes and Depreciation Amortization EBITDA-7.7 M-8.3 M
Earnings before Tax-12.8 M-13.8 M
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company was incorporated in 2006 and is headquartered in Celebration, Florida. Kempharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Kempharm without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Sync Your Broker Now

   

Sync Your Broker

Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Kempharm using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Stocks Correlation. Note that the Kempharm information on this page should be used as a complementary analysis to other Kempharm's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Complementary Tools for Kempharm Stock analysis

When running Kempharm price analysis, check to measure Kempharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kempharm is operating at the current time. Most of Kempharm's value examination focuses on studying past and present price action to predict the probability of Kempharm's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kempharm's price. Additionally, you may evaluate how the addition of Kempharm to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
The market value of Kempharm is measured differently than its book value, which is the value of Kempharm that is recorded on the company's balance sheet. Investors also form their own opinion of Kempharm's value that differs from its market value or its book value, called intrinsic value, which is Kempharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kempharm's market value can be influenced by many factors that don't directly affect Kempharm underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kempharm's value and its price as these two are different measures arrived at by different means. Investors typically determine Kempharm value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kempharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.